Compare GDV & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | TMDX |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2019 |
| Metric | GDV | TMDX |
|---|---|---|
| Price | $28.96 | $86.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $148.22 |
| AVG Volume (30 Days) | 97.4K | ★ 623.7K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.25 |
| Revenue Next Year | N/A | $18.75 |
| P/E Ratio | ★ N/A | $142.07 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $26.14 | $60.11 |
| 52 Week High | $31.00 | $156.00 |
| Indicator | GDV | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.52 | 51.89 |
| Support Level | $28.67 | $80.29 |
| Resistance Level | $29.51 | $95.18 |
| Average True Range (ATR) | 0.41 | 4.40 |
| MACD | -0.12 | -0.41 |
| Stochastic Oscillator | 13.98 | 70.10 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.